Ali Mazloom1, Johannes E Wolff, Arnold C Paulino. 1. Department of Radiation Oncology, The Methodist Hospital, and The Methodist Hospital Research Institute, Houston, TX 77030, USA.
Abstract
PURPOSE: To perform a comprehensive literature review and analysis of cases dealing with choroid plexus carcinoma (CPC) to determine the optimal radiotherapy (RT) treatment field. METHODS AND MATERIALS: A PubMed search of English language articles from 1979 to 2008 was performed, yielding 33 articles with 56 patients who had available data regarding RT treatment field. The median age at diagnosis was 2.7 years (range, 1 month-53 years). Of 54 patients with data regarding type of surgery, 21 (38.9%) had complete resection. Chemotherapy was delivered to 27 (48%) as part of initial therapy. The RT treatment volume was the craniospinal axis in 38 (68%), whole brain in 9 (16%), and tumor/tumor bed in 9 (16%). Median follow-up for surviving patients was 40 months. RESULTS: The 5-year overall survival and progression-free survival (PFS) rates were 59.5% and 37.2%, respectively. Complete resection (p = 0.035) and use of craniospinal irradiation (CSI; p = 0.025) were found to positively affect PFS. The 5-year PFS for patients who had CSI vs. whole brain and tumor/tumor bed RT were 44.2% and 15.3%. For the 19 patients who relapsed, 9 (47%) had a recurrence in the RT field, 6 (32%) had a recurrence outside the RT field, and 4 (21%) had a recurrence inside and outside the irradiated field. CONCLUSION: Patients with CPC who received CSI had better PFS compared with those receiving less than CSI. This study supports the use of CSI in the multimodality management of patients with CPC. Copyright (c) 2010 Elsevier Inc. All rights reserved.
PURPOSE: To perform a comprehensive literature review and analysis of cases dealing with choroid plexus carcinoma (CPC) to determine the optimal radiotherapy (RT) treatment field. METHODS AND MATERIALS: A PubMed search of English language articles from 1979 to 2008 was performed, yielding 33 articles with 56 patients who had available data regarding RT treatment field. The median age at diagnosis was 2.7 years (range, 1 month-53 years). Of 54 patients with data regarding type of surgery, 21 (38.9%) had complete resection. Chemotherapy was delivered to 27 (48%) as part of initial therapy. The RT treatment volume was the craniospinal axis in 38 (68%), whole brain in 9 (16%), and tumor/tumor bed in 9 (16%). Median follow-up for surviving patients was 40 months. RESULTS: The 5-year overall survival and progression-free survival (PFS) rates were 59.5% and 37.2%, respectively. Complete resection (p = 0.035) and use of craniospinal irradiation (CSI; p = 0.025) were found to positively affect PFS. The 5-year PFS for patients who had CSI vs. whole brain and tumor/tumor bed RT were 44.2% and 15.3%. For the 19 patients who relapsed, 9 (47%) had a recurrence in the RT field, 6 (32%) had a recurrence outside the RT field, and 4 (21%) had a recurrence inside and outside the irradiated field. CONCLUSION:Patients with CPC who received CSI had better PFS compared with those receiving less than CSI. This study supports the use of CSI in the multimodality management of patients with CPC. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Authors: Jun Wang; Diana M Merino; Nicholas Light; Brian L Murphy; Yong-Dong Wang; Xiaohui Guo; Andrew P Hodges; Lianne Q Chau; Kun-Wei Liu; Girish Dhall; Shahab Asgharzadeh; Erin N Kiehna; Ryan J Shirey; Kim D Janda; Michael D Taylor; David Malkin; David W Ellison; Scott R VandenBerg; Charles G Eberhart; Rosalie C Sears; Martine F Roussel; Richard J Gilbertson; Robert J Wechsler-Reya Journal: Cancer Res Date: 2019-03-18 Impact factor: 12.701
Authors: Chetan Bettegowda; Owoicho Adogwa; Vivek Mehta; Kaisorn L Chaichana; Jon Weingart; Benjamin S Carson; George I Jallo; Edward S Ahn Journal: J Neurosurg Pediatr Date: 2012-08-31 Impact factor: 2.375
Authors: Miroslava Krzyzankova; Sonja Mertsch; Björn Koos; Astrid Jeibmann; Anne Kruse; Uwe Kordes; Michael C Frühwald; Johannes E Wolff; Werner Paulus; Martin Hasselblatt Journal: J Neurooncol Date: 2012-07-05 Impact factor: 4.130